Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results
Clarus Therapeutics Holdings, a pharmaceutical company focused on androgen and metabolic therapies, will release its fourth quarter and full year 2021 financial results on March 30, 2022, after market closure.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Clarus Therapeutics Holdings, a pharmaceutical company focused on androgen and metabolic therapies, will release its fourth quarter and full year 2021 financial results on March 30, 2022, after market closure. A conference call is scheduled for the same day at 5:15 p.m. ET, accessible via specific dial-in numbers for domestic and international callers. The details will also be available through their Investors section online. Clarus's first commercial product is JATENZO (testosterone undecanoate), aimed at addressing unmet medical needs.
Details
News Market Reaction – CRXT
The recorded move for CRXT in the trading session of this news was +9.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its fourth quarter and full year 2021 financial and operating results on Wednesday, March 30, 2022, after the market closes.
Clarus will host a conference call on Wednesday, March 30, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 5454819. A live webcast and replay of the conference call will be accessible through the Investors section of Clarus Therapeutics’ website at Investors.ClarusTherapeutics.com.
About Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus Therapeutics’ first commercial product is JATENZO® (testosterone undecanoate). For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow us on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).
Clarus Investor Relations Contact:
Kara Stancell
Vice President, Investor Relations & Corporate Communications
kstancell@clarustherapeutics.com
(847) 562-4300 x 206
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.